B00醫療器材、B02手術與治療用醫材

ANEUVO is revolutionizing bioelectronic medicine through innovative neuromodulation therapies that restore independence, improve quality of life, and promote health equity for those with chronic conditions. Our flagship ExaStim® system delivers non-invasive, non-surgical treatment for conditions poorly managed by conventional methods. With CE Certification, we are launching in the EU, focusing first on spinal cord injury (SCI). Our approach is supported by patented technology, strong Level I clinical evidence, and a clear regulatory path. Backed by decades of SCI research and a distinctive revenue model, ANEUVO is uniquely positioned for rapid growth and presents a compelling investment in next-generation healthcare solutions.

ANEUVO’s flagship product, ExaStim®, is a non-surgical, non-invasive neuromodulation system designed to enable functional functional recovery for individuals living with spinal cord injury (SCI)—a condition for which there is currently no cure. Developed for both in-clinic rehabilitation and at-home use, ExaStim® aims to restore voluntary motor control, enhance mobility, and beyond. The system has received CE Certification for use in both acute and chronic SCI patients, supporting applications across the continuum of care. ANEUVO is currently preparing its FDA submission to enter the U.S. market in 2025. With over 650,000 people living with SCI across the U.S. and EU, and 50,000 new cases each year, ExaStim® addresses a critical unmet need within a total addressable market estimated at $6.5 billion.